Sitemap > News > Immunology & Inflammatory Diseases
- Positive Phase I Clinical Results for LCP-Tacro
- Human Genome Sciences and GlaxoSmithKline Initiate Second Phase 3 Clinical Trial of LymphoStat-B® in Systemic Lupus Erythematosus
- Cobalis Announces Delay in Reporting of Phase III Trial Results for PreHistin™ in Seasonal Allergic Rhinitis
- Acorda Therapeutics Begins Second Phase 3 Clinical Trial of Fampridine-SR in Multiple Sclerosis
- Anacor Clinical Study of AN2728, A Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
- BioMS Initiates Enrollment In Pivotal U.S. Phase III MS Trial
- Unigene Reports That Oral Calcitonin Phase III Clinical Study for Osteoarthritis Treatment is Initiated
- Aspreva Announces Fast-Track Designation Granted by the FDA for CellCept in Lupus Nephritis
- Regeneron Submits Biologics License Application To U.S. FDA For IL-1 TRAP (RILONACEPT) For Treatment Of CAPS
- Remicade(R) Receives EU Approval as First and Only Biologic Treatment for Pediatric Crohn's Disease
- Pivotal phase III trial showed RevoladeTM (eltrombopag) raised platelet counts and reduced bleeding in patients with chronic ITP
- Abbott's HUMIRA (Adalimumab) Approved in the European Union for the Treatment of Crohn's Disease
- Opexa Presents Tovaxin Research at Federation of Clinical Immunology Societies Annual Meeting
- Pipex Pharmaceuticals’ Oral TRIMESTA Initiates Enrollment of Phase II/III Clinical Trial for Multiple Sclerosis.
- Human Genome Sciences Reports that a Phase 2 Study of Lymphostat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
- Axcan Pharma Initiates MAX-002 Phase III Clinical Trial to Evaluate the Efficacy and Safety of a High-Concentration 1 Gram Mesalamine Suppository
- GlaxoSmithKlline and Genmab present positive Phase II results with ofatumumab in patients with rheumatoid arthritis (RA)
- Prexige® study shows significantly less impact on blood pressure than ibuprofen in osteoarthritis patients with controlled hypertension
- Actemra: Roche´s novel rheumatoid arthritis drug shows substantial benefits for patients in OPTION study
- ACTEMRA™ (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to A Current Standard of Care
- REMICADE(R) Two Year Data in Ankylosing Spondylitis Show Improvement in Spinal Mobility and Spinal Inflammation
- Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia® (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
- Salix Pharmaceuticals Announces Positive Top Line Results of Balsalazide Tablets Registration Study
- Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory Drugs
- FDA Accepts REMICADE® (Infliximab) Supplemental Biologics License Application for Inhibition of Structural Damage and Improving Physical Function in Patients With Psoriatic Arthritis
- Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin™ for Multiple Sclerosis
- AstraZeneca Announces Symbicort Is Now Available In The U.S.
- Dynavax Starts HEPLISAV(TM) Phase 3 in Europe; U.S. Study; and Phase 2 in ESRD in Canada
- Vasogen Reports on Outcome of FDA Meeting
- SciClone Initiates Phase 2 Clinical Trial Using SCV-07 to Treat Hepatitis C Patients
- Aspreva and Roche Announce Preliminary Results for Phase III Study Evaluating CellCept in Lupus Nephritis
- Isotechnika achieves full enrolment for ISA247 Phase 2b kidney transplant trial
- CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
- NicOx initiates third pivotal naproxcinod phase 3 study
- UCB and Biogen Idec’s oral VLA-4 antagonist (CDP323) enters phase II development for Multiple Sclerosis
- Cytos Biotechnology reports results from phase IIa study with CYT003-QbG10 in patients suffering from atopic dermatitis.
- Anthera Completes Enrollment of "PLASMA" Trial With A-002 and Announces Initiation of new Investigator Study
- Phase III Bronchiectasis Trial Complete
- EMEA approves Kamada’s plans for phase II / III clinical trials of the aerosolized form of AAT for the treatment of Congenital Emphysema
- Genzyme Announces Results of Clinical Trial of Hylastan
- Actemra: latest phase III study shows significant improvement in symptoms of patients with rheumatoid arthritis
- Critical Therapeutics Initiates Phase IV Study Evaluating ZYFLO CR(TM) in Asthma Patients on Inhaled Corticosteroids Whose Symptoms Are Poorly Controlled Printer Friendly Version
- Inspire to Advance Epinastine Nasal Spray to Phase 3
- Barrier Therapeutics Announces Positive Phase 2 Data With Oral Rambazole in Moderate to Severe Psoriasis
- Amira Pharmaceuticals Announces Positive Initial Data from a Phase 1 Study of AM103, A Novel Product Candidate for the Treatment of Respiratory and Cardiovascular Disease
- XOMA Initiates Phase I U.S. Trial in Type 2 Diabetes for XOMA 052, Monoclonal Antibody With Therapeutic Potential in Multiple Inflammatory Diseases
- Can-Fite Reports Results of a Phase IIb Clinical Study in Rheumatoid Arthritis with CF101, an A3 Adenosine Receptor Agonist. The Results Support Further Clinical Development of CF101
- Neurochem receives approvable letter for eprodisate (KIACTA) for treatment of AA amyloidosis
- Elan and Biogen Idec Preparing to Appeal Ruling on European Application for Natalizumab for the Treatment of Crohn's Disease
- Medarex announce that its partner MedImmune has initiated a Phase Ib multi-dose clinical trial of MEDI-545 for the potential treatment of lupus
- Allergy Therapeutics says ragweed hay fever vaccine launch delayed by a year
- MedImmune Announces Interim Phase 1 Study Results for Potential Asthma Therapy
- Isotechnika completes patient recruitment of pivotal Phase 3 psoriasis trial
- BioMS Relapsing-Remitting MS Trial Receives Positive Review From Data Safety Monitoring Board
- Protalex Announces Preliminary Results in Phase I Clinical Trial
- Actemra monotherapy demonstrates significant clinical benefit in patients with rheumatoid arthritis
- Targacept Initiates Phase I Clinical Trial of TC-5619
- Targeted Genetics Provides Update on Inflammatory Arthritis Phase I/II Trial
- Targeted Genetics Provides Update on Inflammatory Arthritis Phase I/II Trial
- FDA Statement on Gene Therapy Clinical Trial
- Joint FDA Advisory Committee Recommends Approval of TYSABRI® for the Treatment of Moderate-to-Severe Crohn’s Disease
- MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
- Macrogenics Begins Global Phase 2/3 Protégé Study In Recent-onset Type 1 Diabetes Mellitus
- FDA allows long term use of ISA247 in Isotechnika Phase 2b kidney transplant trial
- SkyePharma PLC - Flutiform Progress Update
- Phase I Clinical Trial Underway for Welichem Biotech
- ORENCIA® (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
- EPIX Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of First-in-Class 5-HT2B Antagonist in Patients with Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease
- Rilonacept (IL-1 Trap) Granted FDA Priority Review for the Treatment of CAPS
- GSK receives decision from FDA on Advair 500/50 for COPD
- Kiadis Pharma Completes Patient Enrollment of Rhitol phase I/II Clinical Trial
- Isotechnika's independent data monitoring committee conducts second review of Phase 2b kidney transplant trial
- CollaGenex Pharmaceuticals Announces Highly Positive Results of Phase 2 Dose-Finding Trial of Col-118 for the Treatment of Erythema
- AtheroGenics Announces First Patients Enrolled in ANDES Phase III Diabetes Clinical Trial
- Phase III Trial Finds Pharmaxis' Bronchitol Effective
- Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
- Salix Pharmaceuticals Announces Statistically Significant Top–Line Results of a Unique Granulated Mesalamine Product Registration Study in Ulcerative Colitis
- Avigen Initiates European Multi-Center AV650 Phase II Spasticity Trial in Patients with Multiple Sclerosis
- LifeCycle Pharma Initiates Head-to-Head Clinical Trial of LCP-Tacro versus Advagraf
- Alba Therapeutics Announces Clearance of IND for Beta Cell Preservation in Type 1 Diabetes using AT-1001
- Data in the SinuNase Phase 3 Clinical Trial Predicts That Virtually 100% of Chronic Sinusitis Cases Are Due to a Fungal-Induced Inflammation
- Regeneron Announces Positive Results in Exploratory Proof-of-Concept Study of Rilonacept in Chronic Active Gout
- ATL1102 MS Phase IIa Trial Update
- Lev Pharmaceuticals Meets Primary Endpoint in Pivotal Phase III Prophylactic Trial for Hereditary Angioedema
- Opexa Therapeutics Gives Update on Phase IIb Trial of Tovaxin® for Treatment of Multiple Sclerosis
- NicOx reports TOPIGEN to advance TPI-1020 into phase 2 for COPD following promising clinical results
- Genmab Discloses Target and Development Plans for HuMax-Inflam
- XOMA Initiates Phase 1 European Trial in Diabetes for XOMA 052, a Novel Anti-IL-1 Antibody Designed to Target Diabetes, Rheumatoid Arthritis and Other Inflammatory Diseases
- Hollis-Eden Pharmaceuticals Announces Filing of IND for Phase I/II Clinical Trials with HE3286 in Diseases of Inflammation
- Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
- Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
- Alba Therapeutics Announces Phase IIb Clinical Trial for Oral AT-1001 for the Treatment of Celiac Disease
- Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism
- TEVA PROVIDES UPDATE ON EDRATIDE FOR SYSTEMIC LUPUS ERYTHEMATOSUS
- Sucampo Pharmaceuticals Initiates Phase 2, Dose-Finding Trial of Cobiprostone for the Prevention of NSAID-Induced Ulcers in Arthritis Patients
- CollaGenex Pharmaceuticals Announces Highly Positive Results of Phase 2 Dose-Finding Trial of Col-118 for the Treatment of Erythema
- Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
- Pivotal Ustekinumab (CNTO 1275) Phase 3 Data To Debut At World Congress Of Dermatology Meeting
- ISTA Pharmaceuticals Expands Its Pipeline in Allergy Treatments
- DIAMYD® DIABETES VACCINE EFFECTIVE FOR AT LEAST 21 MONTHS
- Alkermes and Indevus Announce Positive Results from Phase 2a Clinical Study of ALKS 27 for the Treatment of COPD
- CombinatoRx Announces Initiation of Phase 2b Clinical Study of CRx-102 in Knee Osteoarthritis
- New prescription allergy treatment XYZAL® (levocetirizine dihydrochloride) now available for fall allergy season in the USA
- Abbott\'s ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
- NicOx and Ferrer present promising clinical and preclinical results in dermatology
- ZymoGenetics and Merck Serono Receive FDA Special Protocol Assessment for Atacicept Pivotal Study in Lupus Nephritis
- PROMISING PHASE 3 TRIAL RESULTS SHOW NOVEL BIOLOGIC THERAPY USTEKINUMAB (CNTO 1275) SIGNIFICANTLY IMPROVED PSORIASIS USTEKINUMAB (CNTO 1275) SIGNIFICANTLY IMPROVED PSORIASIS
- 4SC AG: patient treatment in phase IIa clinical trial completed
- Argenes initiates Phase I clinical study of ARG098 (anti-Fas IgM monoclonal antibody), a novel therapeutics for rheumatoid arthritis, in Europe
- Accentia Announces Investigational New Drug Application for Revimmune Usage in a Pivotal Phase 3 Study of Refractory Multiple Sclerosis
- deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack
- Alcon Amends NDA for Patanase(R) Nasal Spray
- BioMS Medical Presents at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- Critical Therapeutics Announces Enrollment in Phase III Trial of Zileuton in Patients with Acute Exacerbations of COPD
- Elan and Biogen Idec Announce That FDA Will Extend Regulatory Review Period for TYSABRI® for Crohn\'s Disease
- Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
- CLINICAL STUDIES SHOW REMICADE® REDUCES INCIDENCE OF BOWEL SURGERIES IN ULCERATIVE COLITIS PATIENTS
- New Analyses of Long-Term LIALDATM (mesalamine) Data Presented at ACG
- Ocera Therapeutics Announces Positive Results with AST-120 in Pouchitis
- Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis
- Savient Pharmaceuticals Completes Puricase(R) Phase 3 Studies for Treatment-Failure Gout.
- Osiris Therapeutics Receives FDA Clearance to Initiate Phase III Pivotal Trial for Prochymal™ as a First Line Treatment for Acute Graft vs. Host Disease
- DOR BioPharma Receives Not Approvable Letter from FDA for orBec® for Treatment of Gastrointestinal Graft-vs.-Host Disease. DOR Committed to Addressing Unmet Medical Needs of GVHD Patients.
- New allergic rhinitis treatment Avamys™ receives positive opinion in Europe
- Can-Fite to Conduct a Confirmatory Phase IIb Trial in Early 2008 as Part of Ongoing Development of CF101 for the Treatment of Rheumatoid Arthritis
- Dynavax Begins TOLAMBA(TM) Environmental Exposure Chamber Study
- Copaxone® Significantly Decreases Disease Activity In Patients Who Switched From Interferon Beta (Ifnb) Due To Development Of Neutralizing Antibodies (Nabs)
- Osiris Therapeutics Initiates Phase II Clinical Trial Evaluating Prochymal(TM) for Type 1 Diabetes
- LifeCycle Pharma Announces Positive Interim Phase II Clinical Trial Results for LCP-Tacro in Kidney Transplant Patients
- Oglemilast, Glenmark’s lead molecule for Asthma / COPD receives US FDA nod to initiate further
- Peptech successfully completes Phase I trial for PN0621
- Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus
- Peptech successfully completes Phase I trial for PN0621
- MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma
- Revotar reports first positive clinical results from Phase IIa study in COPD
- Theravance Announces Initiation of Phase 2 Clinical Program with its MABA Compound in COPD
- PDUFA Date for Rilonacept (IL-1 Trap) Extended Three Months by FDA
- Data from Completed Phase 1 Studies of Novel Adenosine A2b Antagonist CVT-6883 Show Safety, Tolerability and Potential Utility in Chronic Pulmonary and Inflammatory Diseases
- Millennium Announces MLN1202 Significantly Reduced Marker of Systemic Inflammation and Identifies Genomic Biomarker For Responders
- LifeCycle Pharma Announces Positive Results From Head-to-Head Clinical Trial of LCP-Tacro Versus Advagraf(R) For the Prevention of Organ Rejection After Transplantation
- Initiation Of Enrollment In Pivotal Phase III Clinical Study Of Oral Laquinimod For Relapsing-Remitting Multiple Sclerosis
- FDA grants Kiadis Pharma lead product ATIR orphan drug designation
- CombinatoRx Announces Initiation of Phase 2a Clinical Study of CRx-191 in Psoriasis
- Can-Fite: CF101 may be Effective for the Treatment of Crohn\'s
- BioMS Relapsing-Remitting MS Trial Receives Positive Review From Data Safety Monitoring Board
- Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
- AtheroGenics Modifies ANDES Clinical Trial Discontinuing Highest Dose of AGI-1067
- Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA® (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
- NicOx’ naproxcinod phase 3 results presented
- FDA Approves Nonprescription Zyrtec-D for Allergies
- NSL-101 Phase II Clinical Trial Receives Approval
- Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
- Dynavax Presents New Analysis of TOLAMBA(TM) Data: Analysis Points to Appropriate Patient Selection Criteria for Future Field Trial of TOLAMBA
- BioMS Medical Achieves Enrollment Milestone in U.S. Phase III Multiple Sclerosis Trial
- Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Psoriasis
- Sosei and Vectura Announce Start of Phase II Studies of QVA149 for the Treatment of COPD
- # Abbott\'s HUMIRA® Receives Positive Opinion from EMEA for Treatment of Moderate to Severe Plaque Psoriasis
- Topigen Pharmaceuticals to advance TPI 1020 into Phase 2 development for COPD
- Roche Submits Application for FDA Approval of Actemra for the Treatment of Rheumatoid Arthritis
- Cardiome Initiates Phase 1 Study for GED-aPC
- ATL1102 Phase IIa Multiple Sclerosis Trial Update
- Roche Submits Application for FDA Approval of Actemra for the Treatment of Rheumatoid Arthritis
- Favourable results from GRAZAX® study in children
- Targeted Genetics Announces That FDA Has Removed Hold on Phase I/II Clinical Trial of tgAAC94 for Inflammatory Arthritis
- MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatiod Arthritis
- Oralair® Grasses: Positive results of VO52.06 paediatric study
- Oralair® Grasses: Positive results of VO52.06 paediatric study
- Inspire Initiates Phase 3 Trial of Epinastine Nasal Spray for Allergic Rhinitis
- LifeCycle Pharma Announces New Product Candidate; Initiates Phase I Clinical Trial for Sirolimus, an Immunosuppressant to Prevent Organ Rejection after Transplantation and for the Treatment of Certain Autoimmune Diseases
- Acorda Therapeutics Completes Enrollment of Phase 3 Clinical Trial of Fampridine-SR
- Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Assessment of Its Phase I/II Trial of tgAAC94 for Inflammatory Arthritis
- LifeCycle Pharma Initiates Phase II Clinical Trial for LCP-Tacro, an Immunosuppressant to Prevent Organ Rejection in Liver Transplant Recipients
- Arana Announces Phase II trials for Lead Compound ART621
- Novogen\'s drug for inflammatory bowel disease has positive results following phase Ib trial
- CENTOCOR AND JANSSEN-CILAG SUBMIT APPLICATIONS REQUESTING APPROVAL OF USTEKINUMAB IN THE U.S. AND EUROPE FOR TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS
- Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
- Ligand Presents Positive LGD-4665 Phase I Clinical Trial Results at the American Society of Hematology Annual Meeting (ASH)
- Osiris Therapeutics Reports Positive Results for Prochymal(TM) as a Rescue Agent in Pediatric Patients with End-Stage Graft vs. Host Disease
- HEMISPHERX BIOPHARMA RECEIVES NOTICE OF INCOMPLETE NEW DRUG APPLICATION (NDA)
- Pivotal Phase 3 Romiplostim Study in Splenectomized Patients Meets Primary Endpoints
- Chemokine Therapeutics Continues patient Therapy using CTCE-9908 and Extends Closing of its Phase I/II Clinical Trial
- BioMS Phase III U.S. MS Trial Receives Positive Safety Review from Data Safety Monitoring Board
- Astion Pharma to commence international Phase III clinical studies with ASF-1057 in seborrheic dermatitis.
- ZymoGenetics and Merck Serono Initiate Phase 2/3 Clinical Trial of Atacicept in Lupus Nephritis
- Puricase(R) (pegloticase) Meets Pre-Specified Primary Efficacy Endpoint in Two Replicate Phase 3 Studies
- Rigel\'s R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
- Isis and Excaliard Collaborate to Develop Antisense Drugs for Local Treatment of Fibrotic Diseases.
- Genmab Announces Details of Planned Ofatumumab Phase II Study in Multiple Sclerosis
- NicOx completes enrollment in second pivotal phase 3 study for naproxcinod and provides development update
- Neurochem announces European opinion for Eprodisate (KIACTA) for the treatment of AA amyloidosis
- Collegium Pharmaceutical to Advance its Allergic Rhinitis Product into Phase III Trials
- AtheroGenics Completes Enrollment in ANDES Phase III Clinical Trial of AGI-1067
- Kalypsys Initiates Second Phase I Clinical Trial of Topical iNOS Inhibitor
- GlaxoSmithKline files for FDA approval of Promacta/ Revolade (eltrombopag) to be the first oral platelet growth factor for rare blood disorder
- Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
- Abbott\'s HUMIRA® Approved in the European Union for Treatment of Moderate-to-Severe Plaque Psoriasis
- LifeCycle Pharma Initiates Phase II Clinical Trial of LCP-Tacro for the Treatment of Autoimmune Hepatitis
- GlaxoSmithKline and Theravance Announce Start of Large Phase 2b ICS and LABA Studies for Asthma in the Horizon Programme
- MorphoSys Files Clinical Trial Application to Initiate First Phase 1 Clinical Study of its MOR103 Program
- Accentia\'s CEO Provides Outlook for 2008 including Update on SinuNase Phase 3 Blinded Trial Results on 80% of Patients
- First head-to-head study comparing common treatments for patients with COPD shows quality of life and survival benefits for patients treated with Seretide
- Last patient in Isotechnika\'s phase 2b kidney transplant trial completes six month treatment
- VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
- Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF
- MAP Pharmaceuticals Initiates Phase 3 Clinical Trial of Unit Dose Budesonide in Children with Asthma
- Anika Therapeutics Enrolls First Patient in U.S. Clinical Study for Monovisc(TM)
- Icagen Provides Update for Clinical Development of Senicapoc, a Novel Oral Small Molecule Ion Channel Blocker
- Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
- CollaGenex Pharmaceuticals Initiates Phase 2 Dose-Finding Study of Becocalcidiol for the Treatment of Psoriasis
- CollaGenex Pharmaceuticals Initiates Phase 2 Dose-Finding Study of Becocalcidiol for the Treatment of Psoriasis
- ZymoGenetics Announces Special Protocol Assessment for Atacicept in General SLE
- Kamada Announces Successful Completion of Phase I Studies with Aerosolized AAT for the Treatment of Lung Diseases
- FDA Approves TYSABRI® for the Treatment of Moderate-to-Severe Crohn\'s Disease
- Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
- ALVESCO gains FDA approval for the U.S. market
- YM BIOSCIENCES PROVIDES UPDATE ON AEROLEF™ CLINICAL DEVELOPMENT PROGRAM
- CollaGenex Pharmaceuticals Announces Results of Phase 4 Clinical Study Showing Oracea Equally Effective as 100 mg Doxycycline in Treatment of Rosacea
- OXIS Out-licensed Drug BXT 51072 to Be Developed by Synvista for the Treatment of Psoriasis
- New allergic rhinitis treatment Avamys™ approved in Europe
- Abbott\'s HUMIRA® (adalimumab) Receives FDA Approval for Moderate to Severe Chronic Plaque Psoriasis
- LifeCycle Pharma Announces Transplantation Programs on Track
- ALVESCO® gains FDA approval for the U.S. market
- FDA Approves Labeling Change for Non-Drowsy CLARITIN
- Genentech and Biogen Idec Announce Positive Results from a Phase III Trial of Rituxan in Patients With Rheumatoid Arthritis Who Inadequately Responded to Methotrexate
- Acorda Therapeutics Announces Successful Thorough QT Study of Fampridine-SR
- Sepracor Acquires Exclusive U.S. Rights to Nycomed\'s ALVESCO(R) HFA and OMNARIS(TM) AQ Products as Well as Ciclesonide Pipeline
- Inverseon Announces Positive Phase IIa Asthma Study
- Kiadis Pharma announces successful completion of Rhitol Phase II clinical study
- Topigen Pharmaceuticals Initiates European Phase II Clinical Study of TPI ASM8 in Patients With Asthma
- Immunomedics Announces First Patient Dosing of Veltuzumab, Resulting in a Complete Response, in Immune Thrombocytopenic Purpura
- BioMarck Pharmaceuticals Obtains FDA Agreement on its Phase 2 Clinical Trial Plans
- FDA Approves ASMANEX (R) TWISTHALER(R) (Mometasone Furoate Inhalation Powder) for the Once Daily Maintenance Treatment of Asthma in Children Ages 4-11
- Centocor Submits BLA for Ustekinumab to U.S. FDA
- MediciNova\'s MN-166 Reduces Persistent Black Hole Formation in Multiple Sclerosis Patients
- FDA Agrees to Review Cimzia File for the Treatment of Rheumatoid Arthritis
- Hollis-Eden Pharmaceuticals Commences Phase I/II Clinical Trial in Ulcerative Colitis with Novel Oral Anti-Inflammatory Drug Candidate TRIOLEX
- LA JOLLA PHARMACEUTICAL COMPANY REPORTS PROGRESS IN INTERNATIONAL PHASE 3 RIQUENT STUDY
- DIAMYD UPDATES FDA IND APPROVAL STATUS FOR PHASE III DIAMYD DIABETES STUDY IN THE US
- MorphoSys Receives CTA Approval to Initiate Phase 1 Clinical Study for MOR103 Program
- Critical Therapeutics Provides Update on Launch of ZYFLO CR™ at 2008 BIO CEO & Investor Conference
- Incyte Reports Progress in Multiple Clinical Programs; Expands JAK Inhibitor Program; Announces 2007 Financial Results and Provides 2008 Financial Guidance,
- Alvine Pharmaceuticals Initiates Phase I Trial for ALV003
- POSITIVE INTERIM RESULTS FROM CUPRINDO PHASE 1 CLINICAL TRIALS
- FDA Approves XYZAL® (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
- Glenmark’s molecule for Rheumatoid Arthritis -
- Abbott Receives FDA Approval for HUMIRA® (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis
- Welichem Obtains Approval for Phase IIa Clinical Trial on Eczema
- Circassia Initiates Phase II Clinical Study With Novel Anti-Allergy Technology
- Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema.
- FDA grants Priority Review For Promacta / Revolade (Eltrombopag)
- Array BioPharma Announces Positive Phase 2 Top-Line Results in Inflammatory Pain Clinical Trial
- FDA Grants Market Clearance to Aerocrine Inc.’s NIOX MINO: a New Hand-Held Device to Measure Airway Inflammation in Asthma
- Ception Therapeutics Initiates Phase II/III Clinical Trial for Its Lead Product Reslizumab in Eosinophilic Esophagitis (EE) in Children
- BioMS Medical\'s Relapsing-Remiting
- Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis
- KaloBios Initiates Phase 1/2 Trial of KB002 Engineered Monoclonal Antibody in Persistent Asthma
- Opexa Therapeutics Announces Completion of Mid Study Descriptive Analysis on Phase IIb Trial of Tovaxin for Treatment of Multiple Sclerosis
- CombinatoRx Drug Candidate CRx-191 Demonstrates Positive Phase 2 Results in Psoriasis
- Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis.
- DIAMYD GETS AUTHORIZATION TO BEGIN PHASE III STUDY IN THE US
- ALK-Abelló, the makers of GRAZAX®, Present Successful Phase III Clinical Study Results with Children
- TorreyPines Therapeutics Initiates Phase II Study of
- Archemix Announces Initiation of Phase 2 Trial for Aptamer Product Candidate ARC1779 in Patients with TTP, a Rare, Life-Threatening Blood Disorder
- Sepracor Presents OMNARIS(TM) HFA Nasal Aerosol Large-Scale Phase II Study Data at American Academy of Allergy Asthma and Immunology
- Phase III study of Bosatria (mepolizumab) showed disease control with reduced corticosteroid use in hypereosinophilic syndrome
- Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
- Targeted Genetics Announces Completion of Dosing for the Phase 1/2 Clinical Trial of tgAAC94 for Inflammatory Arthritis
- MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
- VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial
- CHMP Upholds Negative Opinion for the EU Application for Cimzia in the Treatment of Crohn\'s Disease
- Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
- MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
- Array BioPharma Advances p38 / Tie2 Inhibitor, ARRY-614, into Phase 1 Clinical Trial
- ANACOR PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM PHASE 2A CLINICAL TRIAL OF AN2728 IN PSORIASIS PATIENTS
- Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
- Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
- MediciNova Initiates Phase II Clinical Trial of MN-221 in Status Asthmaticus Patients
- ATL1102 Phase IIa MS Trial Update
- Can-Fite: First Patient was enrolled to the Phase IIb Rheumatoid Arthritis Trial
- VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
- EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
- MediciNova Reports Clinical Results From Two-Year Phase II Clinical Trial of MN-166 in Multiple Sclerosis
- Urigen Announces Early Closure of URG101 Phase II Clinical Trial based on Positive Interim Analysis Results
- MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics
- Phase III MS Neuropathic Pain Trial Preliminary Results
- Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
- Kamada was Granted New Orphan Drug Designation by the FDA, for its Aerosolized AAT for the treatment of Bronchiectasis
- Critical Therapeutics Completes Phase I Clinical Trial of the R(+) Isomer of Zileuton
- Collegium Pharmaceutical Announces FDA Filing for AllerNase™, a Nasal Inhaled Steroid for the Treatment of Allergic Rhinitis
- B·R·A·H·M·S Receives Final FDA Clearance To Market Procalcitonin (PCT)
- U.S. Food and Drug Administration Approves ORENCIA® (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
- Genentech and Biogen Idec Announce Top-Line Results from a Phase II/III Clinical Trial of Rituxan in Primary-Progressive Multiple Sclerosis
- BioMS Medical’s Phase III U.S. Multiple Sclerosis Trial Receives Positive Safety Review from Data Safety Monitoring Board
- Alcon\'s PATANASE(R) Nasal Spray Approved by FDA for Treatment of Nasal Allergy Symptoms
- MedImmune Advances Asthma Program With Start of a Phase 2 Trial in Europe and Australia and First U.S.-based Clinical Trial for Antibody Targeting IL-13
- Opexa Therapeutics Presents Tovaxin Phase I/II Data at the American Academy of Neurology 60th Annual Meeting
- Actemra approved in Japan to treat patients with rheumatoid arthritis
- Lexicon\'s Drug Candidate for Rheumatoid Arthritis, LX2931, Shows Positive Results in Phase 1 Clinical Trial
- EARLY TREATMENT WITH COPAXONE® SIGNIFICANTLY DELAYED PROGRESSION TO CLINICALLY DEFINITE MULTIPLE SCLEROSIS
- ANP completes ATL1102 Phase IIa Multiple Sclerosis Trial
- Aldagen Announces Initiation of ALD-101 Phase III Trial for Improving Cord Blood Transplants in Pediatric Patients with Inherited Metabolic Diseases
- Cimzia Approved in the US for the Treatment of Moderate to Severe Crohn\'s Disease
- InterMune Announces Progress on Pirfenidone in IPF
- Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
- Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast
- MorphoSys Announces Completion of First Dosing in Phase 1 Trial for MOR103 Program
- Ligand Initiates Phase II Trial with LGD-4665 in Idiopathic Thrombocytopenic Purpura
- LA JOLLA PHARMACEUTICAL ANNOUNCES POSITIVE 12-MONTH INTERIM ANTIBODY DATA AND PROVIDES UPDATE FOR ONGOING RIQUENT PHASE 3 \"ASPEN\" LUPUS TRIAL
- KaloBios Completes Patient Dosing in its U.S. Phase 1 Trial of Its Third Drug Candidate: KB003
- Genentech and Biogen Idec Announce Top-Line Results From Phase II/III Clinical Study of Rituxan in Systemic Lupus Erythematosus
- Merck Serono and ZymoGenetics Initiate Atacicept Phase 2 Clinical Trial in Relapsing Multiple Sclerosis
- MERCK SERONO ANNOUNCES INITIATION OF PHASE II CLINICAL TRIAL OF ATACICEPT IN RELAPSING MULTIPLE SCLEROSIS
- ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
- FDA approves Advair 250/50 for reduction of exacerbations in patients with COPD
- Genentech and Biogen Idec Announce Top-Line Results From Phase II/III Clinical Study of Rituxan in Systemic Lupus Erythematosus
- N30 Pharmaceuticals, LLC announces completion of Phase 1 clinical studies with N30-201
- Savient Reports Favorable Interim Data from Puricase (pegloticase) Open Label Extension Study
- Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis
- Osiris Receives Approval for Use of Prochymal Under FDA Expanded Access Treatment Program
- FDA Grants Priority Review of Gamunex as a Treatment for Neurological Disorder CIDP
- Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
- Pipex Pharmaceuticals Receives FDA Orphan Drug Designation For Oral TTM For Idiopathic Pulmonary Fibrosis
- ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 Drug Represents Potential New Approach for the Treatment of Inflammatory Disease
- Pivotal Phase III Pollinex® Quattro grass study meets primary efficacy endpoint
- View Summary Dynavax TOLAMBA(TM) Chamber Study Misses Primary Endpoint; Company Updates 2008 Financial Outlook
